339 related articles for article (PubMed ID: 22983396)
1. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Kwong LN; Costello JC; Liu H; Jiang S; Helms TL; Langsdorf AE; Jakubosky D; Genovese G; Muller FL; Jeong JH; Bender RP; Chu GC; Flaherty KT; Wargo JA; Collins JJ; Chin L
Nat Med; 2012 Oct; 18(10):1503-10. PubMed ID: 22983396
[TBL] [Abstract][Full Text] [Related]
2. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
3. A Preexisting Rare
Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
[TBL] [Abstract][Full Text] [Related]
4. Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism.
Li A; Ma Y; Jin M; Mason S; Mort RL; Blyth K; Larue L; Sansom OJ; Machesky LM
J Invest Dermatol; 2012 Nov; 132(11):2610-21. PubMed ID: 22718121
[TBL] [Abstract][Full Text] [Related]
5. Targeting the RAS pathway in melanoma.
Ji Z; Flaherty KT; Tsao H
Trends Mol Med; 2012 Jan; 18(1):27-35. PubMed ID: 21962474
[TBL] [Abstract][Full Text] [Related]
6. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
Robinson JP; Rebecca VW; Kircher DA; Silvis MR; Smalley I; Gibney GT; Lastwika KJ; Chen G; Davies MA; Grossman D; Smalley KSM; Holmen SL; VanBrocklin MW
Melanoma Res; 2017 Dec; 27(6):545-557. PubMed ID: 29076949
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
VanBrocklin MW; Robinson JP; Lastwika KJ; Khoury JD; Holmen SL
Pigment Cell Melanoma Res; 2010 Aug; 23(4):531-41. PubMed ID: 20444198
[TBL] [Abstract][Full Text] [Related]
8. Blebs promote cell survival by assembling oncogenic signalling hubs.
Weems AD; Welf ES; Driscoll MK; Zhou FY; Mazloom-Farsibaf H; Chang BJ; Murali VS; Gihana GM; Weiss BG; Chi J; Rajendran D; Dean KM; Fiolka R; Danuser G
Nature; 2023 Mar; 615(7952):517-525. PubMed ID: 36859545
[TBL] [Abstract][Full Text] [Related]
9.
Jenkins RW; Sullivan RJ
Melanoma Manag; 2016 Mar; 3(1):47-59. PubMed ID: 30190872
[TBL] [Abstract][Full Text] [Related]
10. Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma.
Vendramin R; Katopodi V; Cinque S; Konnova A; Knezevic Z; Adnane S; Verheyden Y; Karras P; Demesmaeker E; Bosisio FM; Kucera L; Rozman J; Gladwyn-Ng I; Rizzotto L; Dassi E; Millevoi S; Bechter O; Marine JC; Leucci E
J Exp Med; 2021 Sep; 218(9):. PubMed ID: 34287642
[TBL] [Abstract][Full Text] [Related]
11. STAT3 Relays a Differential Response to Melanoma-Associated
Kim J; Novak D; Sachpekidis C; Utikal J; Larribère L
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31906480
[TBL] [Abstract][Full Text] [Related]
12. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.
Pedersen M; Küsters-Vandevelde HVN; Viros A; Groenen PJTA; Sanchez-Laorden B; Gilhuis JH; van Engen-van Grunsven IA; Renier W; Schieving J; Niculescu-Duvaz I; Springer CJ; Küsters B; Wesseling P; Blokx WAM; Marais R
Cancer Discov; 2013 Apr; 3(4):458-469. PubMed ID: 23303902
[TBL] [Abstract][Full Text] [Related]
13. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Louveau B; Reger De Moura C; Jouenne F; Sadoux A; Allayous C; Da Meda L; Bernard-Cacciarella M; Baroudjian B; Lebbé C; Mourah S; Dumaz N
Melanoma Res; 2024 Apr; 34(2):186-192. PubMed ID: 38141200
[TBL] [Abstract][Full Text] [Related]
14. Kaposiform lymphangiomatosis effectively treated with MEK inhibition.
Foster JB; Li D; March ME; Sheppard SE; Adams DM; Hakonarson H; Dori Y
EMBO Mol Med; 2020 Oct; 12(10):e12324. PubMed ID: 32894644
[TBL] [Abstract][Full Text] [Related]
15. Insights Image for "Treatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition".
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):2117. PubMed ID: 37550488
[No Abstract] [Full Text] [Related]
16. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
17. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
Burd CE; Liu W; Huynh MV; Waqas MA; Gillahan JE; Clark KS; Fu K; Martin BL; Jeck WR; Souroullas GP; Darr DB; Zedek DC; Miley MJ; Baguley BC; Campbell SL; Sharpless NE
Cancer Discov; 2014 Dec; 4(12):1418-29. PubMed ID: 25252692
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
19. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of lung cancers harboring NRAS mutations.
Ohashi K; Sequist LV; Arcila ME; Lovly CM; Chen X; Rudin CM; Moran T; Camidge DR; Vnencak-Jones CL; Berry L; Pan Y; Sasaki H; Engelman JA; Garon EB; Dubinett SM; Franklin WA; Riely GJ; Sos ML; Kris MG; Dias-Santagata D; Ladanyi M; Bunn PA; Pao W
Clin Cancer Res; 2013 May; 19(9):2584-91. PubMed ID: 23515407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
